再程调强适形放疗联合尼妥珠单抗治疗放化疗后局部复发食管癌临床报道及文献复习  

Combined intensity modulated re-radiation plus nimotuzumab as salvage treatment for local recurrent esophageal cancer after chemoradiotherapy： clinical report and review of the literature

作　　者：曹建忠[1] 郭汝元[1] 梁玉[1] 刘宝[1] 张霞琴[1] 宋欣[1] 兰胜民[1] 李红卫[1] 

机构地区：[1]山西省肿瘤医院山西医科大学附属肿瘤医院放射治疗中心,太原030013

出　　处：《肿瘤研究与临床》2015年第1期19-23,共5页Cancer Research and Clinic

基　　金：山西省基础研究项目青年科技研究基金（2012021030-3）

摘　　要：目的探讨再程调强放疗联合尼妥珠单抗治疗食管癌首程放化疗后复发的临床可行性。方法79岁的女性食管鳞状细胞癌患者接受同步放化疗后13个月出现局部复发，给予调强适形放疗（54Gy／30次），并同步予尼妥珠单抗（200mg／次，1次／周，静脉注射，共用6次）。观察疗效及不良反应并进行文献复习。结果再程放疗联合尼妥珠单抗治疗后1个月复查，复发病变完全缓解，除Ⅱ级急性放射性食管炎、Ⅰ级疲劳、Ⅰ级皮疹外，无其他严重不良反应发生。结论再程调强适形放疗联合尼妥珠单抗治疗放化疗后局部复发食管癌具有安全性和有效性，值得进一步探讨。Objective To investigate the clinical feasibility of combined concurrently intensity modulated re-radiation plus nimotuzumab for esophageal cancer patient with locoregional failure after chemoradiotherapy. Methods The case of a 79-year-old female with esophageal squamous cancer diagnosed 13 months prior was presented. Concurrent chemoradiotherapy had been administered. The patient showed local recurrence. Intensity modulated radiation therapy （54 Gy/30 fractions） plus nimotuzumab （200 mg, Week 1-6, intravenously） was administered. The curative effect and adverse reactions were observed. Results One month after treatment, objective efficacy evaluation indicated that the patient achieved complete remission. No severe acute toxicities were found except for grade 2 acute radiation esophagitis, grade 1 fatigue and grade 1 rash. Conclusion The present case indicates that combined treatment of intensity modulated radiation therapy and nimotuzumab may be a safe and effective option for esophageal cancer with locoregional failure after chemoradiotherapy.

关 键 词：食管肿瘤 复发 放射疗法 调强适形 挽救疗法 尼妥珠单抗 

分 类 号：R735.1[医药卫生—肿瘤]